Decitabine and cedazuridine combination therapy in the treatment of acute myeloid leukemia: an evaluation of current evidence

Decitabine-cedazuridine is an oral fixed-dose combination developed to achieve systemic decitabine exposure comparable to intravenous (IV) decitabine through inhibition of cytidine deaminase by cedazuridine. In combination with venetoclax, it enables a fully oral hypomethylating agent (HMA)-venetoclax regimen for older adults and patients with acute myeloid leukemia (AML) who are unsuitable for intensive chemotherapy. Pharmacokinetic bridging studies demonstrated exposure equivalence between oral decitabine-cedazuridine and IV decitabine, while subsequent prospective studies established the feasibility, safety, and clinical activity of the oral combination with venetoclax. The principal advantage of this approach is reduced reliance on parenteral HMA administration rather than demonstrated superiority in antileukemic efficacy or tolerability compared with established HMA-venetoclax regimens. Myelosuppression and infectious complications remain the dominant toxicities and frequently necessitate response-adapted treatment modifications, treatment delays, growth-factor support, and ongoing monitoring. Emerging data are now extending the use of decitabine-cedazuridine as an oral backbone for post-transplant maintenance strategies and molecularly targeted combination regimens incorporating targeted agents, including menin and FLT3 inhibitors. This review summarizes the pharmacology, pharmacokinetics, clinical efficacy, safety, practical administration, and evolving role of decitabine-cedazuridine in AML, while highlighting current evidence gaps and priorities for future research.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-11-14
DOI
https://doi.org/10.1080/14796694.2026.2763959
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Decitabine and cedazuridine combination therapy in the treatment of acute myeloid leukemia: an evaluation of current evidence

Farhad Ravandi, Thura Win Htut, Guillermo Garcia‐Manero
Future Oncology
Acute Myeloid Leukemia Research
article

Decitabine and cedazuridine combination therapy in the treatment of acute myeloid leukemia: an evaluation of current evidence

Farhad Ravandi, Thura Win Htut, Guillermo Garcia‐Manero
article en

Abstract

Decitabine-cedazuridine is an oral fixed-dose combination developed to achieve systemic decitabine exposure comparable to intravenous (IV) decitabine through inhibition of cytidine deaminase by cedazuridine. In combination with venetoclax, it enables a fully oral hypomethylating agent (HMA)-venetoclax regimen for older adults and patients with acute myeloid leukemia (AML) who are unsuitable for intensive chemotherapy. Pharmacokinetic bridging studies demonstrated exposure equivalence between oral decitabine-cedazuridine and IV decitabine, while subsequent prospective studies established the feasibility, safety, and clinical activity of the oral combination with venetoclax. The principal advantage of this approach is reduced reliance on parenteral HMA administration rather than demonstrated superiority in antileukemic efficacy or tolerability compared with established HMA-venetoclax regimens. Myelosuppression and infectious complications remain the dominant toxicities and frequently necessitate response-adapted treatment modifications, treatment delays, growth-factor support, and ongoing monitoring. Emerging data are now extending the use of decitabine-cedazuridine as an oral backbone for post-transplant maintenance strategies and molecularly targeted combination regimens incorporating targeted agents, including menin and FLT3 inhibitors. This review summarizes the pharmacology, pharmacokinetics, clinical efficacy, safety, practical administration, and evolving role of decitabine-cedazuridine in AML, while highlighting current evidence gaps and priorities for future research.

Future Oncology
The University of Texas MD Anderson Cancer Center (US)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon